TriSalus Life Sciences, Inc. (TLSI) Spending and interest coverage
- R&D / revenue · 12 months: Value 32.45%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 23.75%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 32.45% | Research and development expense / revenue. Period ending 2026-06-30. $14.63M ÷ $45.08M × 100 ≈ 32.45% |
| Stock-based compensation / revenue · 12 months | 23.75% | Share-based compensation / revenue. Period ending 2026-06-30. $10.71M ÷ $45.08M × 100 ≈ 23.75% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 14.63M USD | Research and Development Expense |
| Revenue | 45.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 10.71M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -30.51M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.63M | $45.08M | $10.71M | $-30.51M | (m) | 32.45% | 23.75% | (m) | (m) |
| 2026-03-31 | $15.16M | $44.88M | $9.98M | $-28.03M | (m) | 33.78% | 22.24% | (m) | (m) |
| 2025-12-31 | $14.96M | $45.15M | $9.13M | $-26.95M | (m) | 33.14% | 20.22% | (m) | (m) |
| 2025-09-30 | $15.35M | $40.21M | $8.63M | $-31.25M | (m) | 38.19% | 21.47% | (m) | (m) |
| 2025-06-30 | $14.40M | $35.99M | $6.59M | $-30.98M | (m) | 40.00% | 18.32% | (m) | (m) |
| 2025-03-31 | $15.14M | $32.14M | $5.97M | $-31.82M | (m) | 47.10% | 18.59% | (m) | (m) |
| 2024-12-31 | $17.69M | $29.43M | $5.44M | $-36.16M | (m) | 60.10% | 18.49% | (m) | (m) |
| 2024-09-30 | $22.17M | $26.89M | $4.74M | $-42.51M | (m) | 82.46% | 17.64% | (m) | (m) |
| 2024-06-30 | $27.53M | $24.74M | $3.62M | $-52.45M | $887.00K | 111.29% | 14.64% | -59.14× | Reported |
| 2024-03-31 | $29.73M | $21.98M | $2.41M | $-55.71M | $14.00K | 135.21% | 10.98% | -3979.57× | Reported |
| 2023-12-31 | $29.51M | $18.51M | $1.40M | $-54.15M | $16.00K | 159.42% | 7.57% | -3384.38× | Reported |
| 2023-09-30 | (m) | (m) | (m) | $-18.11M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | $-4.06M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | $-2.92M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $-2.75M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | $-2.53M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | $-2.91M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | $-3.40M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $-3.04M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |